[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"iron-overload\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:iron-overload":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,49,72,101,123],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":29,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":37,"lastUpdatePostDateStruct":38,"startDateStruct":41,"completionDateStruct":43,"leadSponsor":45,"locationsCount":48},"100595104","impact-of-iron-overload-on-the-incidence-of-liver-complications-in-long-term-survivors-10-years-of-allogeneic-hematopoietic-stem-cell-transplantation-100595104",false,"NCT07028112","Impact of Iron Overload on the Incidence of Liver Complications in Long-Term Survivors (≥10 Years) of Allogeneic Hematopoietic Stem-Cell Transplantation.","Impact de la Surcharge en Fer Sur l'Incidence Des Complications hépatiques Chez Les Patients allogreffés de Cellules Souches hématopoïétiques à Plus de 10 Ans de la Greffe","AlloFer","Inclusion Criteria:\n\n* Age ≥ 18 years at enrollment\n* Allogeneic HSCT performed at Hôpital Saint Louis between 2004\u002F01\u002F01 and 2014\u002F12\u002F31\n* Alive and attending routine annual follow up within the two years of the study\n* Having given his non-opposition to study after understand overall aims\n* With health insurance coverage\n* Follow up consultation at Saint-Louis Hospital\n\nExclusion Criteria:\n\n* Patient under legal protection (protection of the court, or in curatorship or guardianship).\n\nnot in relapse of the hematological disease at the time of inclusion.\n\n• Patients under 45 Kg","ALL","18 Years",{"count":20,"type":21},500,"ESTIMATED","OBSERVATIONAL","This single-center, non interventional cohort study investigates whether chronic iron overload influences the incidence of liver complications in adults who are at least 10 years beyond allogeneic hematopoietic stem cell transplantation (allo HSCT). Approximately 400-500 survivors transplanted at Hôpital Saint Louis between January 2004 and December 2014 will be evaluated. Transplant characteristics, prior iron overload therapy, and historical hepatic events will be collected through the Promise database. At the same time, the prospective visit will include laboratory panels and non invasive liver stiffness measurement by FibroScan or shear wave elastography. The study's primary objective is to assess the impact of iron overload on the incidence of hepatic complications in patients more than 10 years after an allogeneic hematopoietic stem cell transplantation. Secondary aims include describing the spectrum and frequency of hepatic complications, determining risk factors (including graft versus host disease, conditioning regimen, and comorbidities), and evaluating the long term effectiveness of previous iron reduction treatments (phlebotomy or chelation). Results will clarify whether monitoring and treating iron overload in long term allo HSCT survivors can prevent late hepatic morbidity.",[25,26,27,28],"Iron Overload","Hemosiderosis","Liver Diseases","Hematopoietic Stem Cell Transplantation (HSCT)",[30,31,32,33,34,35],"Iron overload","Liver fibrosis","Elastography","Long-term complications","Allogeneic hematopoietic stem-cell transplantation","graft-versus-host disease","RECRUITING","2026-04-22",{"date":39,"type":40},"2026-04-27","ACTUAL",{"date":42,"type":40},"2025-08-20",{"date":44,"type":21},"2027-08-20",{"name":46,"class":47},"Assistance Publique - Hôpitaux de Paris","OTHER",1,{"id":50,"slug":51,"hasResults":11,"nctId":52,"briefTitle":53,"officialTitle":53,"acronym":4,"eligibilityCriteria":54,"healthyVolunteers":55,"sex":17,"minAge":56,"maxAge":4,"enrollmentInfo":57,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":59,"conditions":60,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":48},"100461885","fully-automated-high-throughput-quantitative-mri-of-the-liver-100461885","NCT05294471","Fully Automated High-Throughput Quantitative MRI of the Liver","Eligibility Criteria for Substudies 1, 2, 4, 5\n\nInclusion Criteria:\n\n* Age 18 years or older\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n\nEligibility Criteria for Substudy 3\n\nInclusion Criteria:\n\n* Age 7 years or older\n* One of:\n\n  * Known or suspected liver iron overload\n  * Known or suspected elevated liver fat\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Patients requiring intravenous (IV) conscious sedation for imaging are not eligible; patients requiring mild, oral anxiolytics for the MRI will be allowed to participate as long as the following criteria are met:\n\n  * The subject has their own prescription for the medication.\n  * The informed consent process is conducted prior to the self-administration of this medication\n  * They come to the research visit with a driver\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)\n\nEligibility Criteria for Substudy 6\n\nInclusion Criteria:\n\n* Age 7 years or older\n* Scheduled for a clinical abdominal MRI exam\n\nExclusion Criteria:\n\n* Patients with contraindication to MRI (e.g. pacemaker, contraindicated metallic implants, claustrophobia, etc)\n* Sedation required for MRI\n* Pregnant or trying to become pregnant (as determined by self-report during MRI safety screening)",true,"7 Years",{"count":58,"type":21},200,"The purpose of this research is to see if a new automated magnetic resonance imaging (MRI) method will be able to improve the images taken of the liver. Participants will have either known or suspected liver disease, known or suspected iron overload syndrome, or be a healthy adult. Participants will be in the research study for one day.",[61,25,62],"Healthy","Liver Fat","2026-03-09",{"date":65,"type":40},"2026-03-12",{"date":67,"type":40},"2023-10-16",{"date":69,"type":21},"2026-09",{"name":71,"class":47},"University of Wisconsin, Madison",{"id":73,"slug":74,"hasResults":11,"nctId":75,"briefTitle":76,"officialTitle":77,"acronym":78,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":80,"enrollmentInfo":81,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":90,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":4},"100620073","evaluation-of-the-quality-of-life-in-patients-with-chronic-iron-overload-due-to-hemoglobinopathies-in-greece-100620073","NCT07352878","Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece.","Evaluation of the Quality of Life in Patients With Chronic Iron Overload Due to Hemoglobinopathies in Greece, Who Are Under Treatment With Deferasirox, Based on Standard Clinical Practice.","FEROUSA","Inclusion Criteria:\n\n* 1\\. Adult patients (≥ 18 years). 2. Patients with major beta-thalassemia with iron overload due to frequent blood transfusions (≥7 ml\u002Fkg\u002Fmonth of packed red blood cells).\n\n  3\\. Patients with chronic iron overload due to blood transfusions if deferoxamine therapy is contraindicated or insufficient in the following patient groups:\n  * adult patients with major beta-thalassemia with iron overload due to infrequent blood transfusions (\\\u003C7 ml\u002Fkg\u002Fmonth of packed red blood cells).\n  * adult patients with other types of anemia.\n\n    4\\. Patients with non-transfusion-dependent thalassemia syndromes with chronic iron overload requiring chelation therapy when deferoxamine therapy is contraindicated or insufficient.\n\n    5\\. Patients who were receiving deferasirox before their inclusion in the study (90, 180, 360, 900 mg) and at their inclusion require treatment with deferasirox at least 900 mg, as part of the treatment of chronic iron overload and according to the SPC.\n\n    6\\. Consent and compliance of participants with the treatments and procedures of the study.\n\n    7\\. Patients for whom data from the last six months from the date of inclusion (medical history, concomitant medication) are available to determine the endpoints.\n\nExclusion Criteria:\n\n* 1\\. Patients under 18 years of age. 2. Patients with myelodysplastic syndromes. 3. Patients with a contraindication to taking deferasirox 90, 180, 360, 900 mg according to the drug's SmPC.\n\n  4\\. Patients receiving or expect to receive another chelating agent (e.g. deferoxamine, deferiprone) in addition to deferasirox, during the study.\n\n  5\\. Patients with a history of mental illness, substance abuse, to a degree that may prevent their participation in the study.\n\n  6\\. Patients are participating in another research protocol.","100 Years",{"count":82,"type":21},150,"This observational clinical study aims to evaluate the HRQoL of thalassemia patients with iron overload in Greece, who are under treatment with deferasirox based on standard clinical practice.",[85,25],"Thalassemia",[87,88,89],"quality of life","iron overload","treatment satisfaction","NOT_YET_RECRUITING","2026-01-13",{"date":93,"type":40},"2026-01-20",{"date":95,"type":21},"2026-04-15",{"date":97,"type":21},"2027-12-31",{"name":99,"class":100},"Elpen Pharmaceutical Co. Inc.","INDUSTRY",{"id":102,"slug":103,"hasResults":11,"nctId":104,"briefTitle":105,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":55,"sex":17,"minAge":18,"maxAge":108,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":111,"conditions":112,"keywords":4,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":48},"100527349","heme-and-non-heme-iron-intakes-gut-microbiota-and-influence-on-host-iron-absorption-100527349","NCT06146608","Heme and Non-heme Iron Intakes, Gut Microbiota, and Influence on Host Iron Absorption","FeMicrobiome","Inclusion Criteria:\n\n* Healthy adults\n* Age between 18- 40y\n* Non-smoking\n* Not currently taking vitamin, mineral, prebiotic, and probiotic supplements.\n* Females: premenopausal and not pregnant or lactating\n* No preexisting medical complications (such as eating disorders, hemoglobinopathies, malabsorption diseases, steroid use, substance abuse history, or taking medications known to influence iron homeostasis)\n* Body mass index (BMI) between 18 - 27 kg\u002Fm2.\n\nExclusion Criteria:\n\n* BMI \\\u003C18 or \\> 27 kg\u002Fm2,\n* Age \\\u003C18 y or \\> 40y,\n* Smoking\n* Pregnancy, lactating\n* Have gastrointestinal disorders\u002Fmalabsorption diseases\u002Fhemoglobinopathies\u002Fdietary restrictions\u002Fsteroid use\u002F medication use of medications known to impact iron status, iron utilization or inflammatory status\n* Currently take vitamin, mineral, prebiotic, and probiotic supplements.\n* Recently received antibiotic treatment","40 Years",{"count":110,"type":21},120,"The FeMicrobiome study will evaluate gut microbiome features and their relationships with dietary iron absorption in healthy adults. The investigators hypothesize that (1) the gut microbiota can be shaped by the heme and non-heme Fe content of the diet and that (2) this will influence individual variation in dietary Fe absorption.",[113,25],"Anemia, Iron Deficiency","2025-02-21",{"date":116,"type":40},"2025-02-24",{"date":118,"type":40},"2023-01-15",{"date":120,"type":21},"2026-01-14",{"name":122,"class":47},"Cornell University",{"id":124,"slug":125,"hasResults":11,"nctId":126,"briefTitle":127,"officialTitle":128,"acronym":129,"eligibilityCriteria":130,"healthyVolunteers":11,"sex":17,"minAge":131,"maxAge":4,"enrollmentInfo":132,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":134,"conditions":135,"keywords":153,"overallStatus":36,"whyStopped":4,"lastUpdateSubmitDate":168,"lastUpdatePostDateStruct":169,"startDateStruct":171,"completionDateStruct":173,"leadSponsor":175,"locationsCount":48},"100561944","neurodegenerative-diseases-progression-markers-markers-ndd-100561944","NCT06596746","Neurodegenerative Diseases Progression Markers (MARKERS-NDD)","Neurodegenerative Diseases Progression Markers (MARKERS-NDD): a Real-world Data Longitudinal Prospective Study","MARKERS-NDD","Inclusion Criteria:\n\n* Patients with diagnosis of Parkinson's Disease, Parkinsonism and Movement Disorders\n\n  * Patients with diagnosis of Parkinson's Disease\n\n    * Diagnosis of Parkinson's Disease according to the United Kingdom (UK) Parkinson's Disease Society Brain Bank\n  * Diagnosis of Movement Disorder not related to Parkinson's Disease\n\n    * Diagnosis of Multiple System Atrophy (MSA) in accordance with Second Consensus Statement on Diagnosis of Multiple System Atrophy;\n    * Diagnosis of Progressive Supranuclear Palsy according to Movement Disorder Society for Diagnosis of Progressive Supranuclear Palsy;\n    * Diagnosis of Essential Tremor\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n* Patients affected by cognitive impairment (CI) and dementia\n\n  * Diagnosis of probable:\n\n    * Lewy Body Dementia\n    * Alzheimer's Disease\n    * Mild Cognitive Decline\n    * Subjective memory complaints\n    * Willing to participate in the study, understand the procedures and sign the informed consent.\n\nExclusion Criteria:\n\n* There are no restrictions for participation in the study based on age, severity of illness or presence of cognitive impairment, as long as the person is able to complete the research assessments.","10 Years",{"count":133,"type":21},600,"MARKERS-NDD is a prospective, observational, longitudinal study, which aims to collect data from patients affected by neurodegenerative diseases (NDD) followed longitudinally for routine examinations performed as part of normal clinical practice. Data collected from clinical evaluations, movement analysis, brain imaging, neuropsychological and electroencephalographic assessments, blood chemistry tests will be analysed to carry out statistical investigations and predictive analyses, also using artificial intelligence systems, which allow the identification of new early markers of diagnosis and prognosis of neurodegenerative diseases.",[136,137,138,139,140,141,142,143,144,145,146,147,148,149,150,151,25,152],"Neurodegenerative Diseases","Parkinson Disease","Synucleinopathies","Lewy Body Disease","Multiple System Atrophy","Tauopathies","Alzheimer Disease","Corticobasal Degeneration","Supranuclear Palsy, Progressive","Atypical Parkinsonism","TDP-43 Proteinopathies","Amyotrophic Lateral Sclerosis","Frontotemporal Lobar Degeneration","Movement Disorders","Cognitive Impairment","Dementia","Neurodegeneration With Brain Iron Accumulation (NBIA)",[136,154,155,156,157,158,159,160,161,162,163,164,165,166,167],"Markers","Gait analysis","Wearable inertial sensors","IMU","Artificial intelligence","AI-Video gait analysis","Handwriting analysis","Voice-based artificial intelligence systems","imaging","multimodal analysis","electroencephalogram","cortical activity","gut microbiota","laboratory blood chemistry parameters","2024-09-11",{"date":170,"type":40},"2024-09-19",{"date":172,"type":21},"2024-09-09",{"date":174,"type":21},"2034-09-09",{"name":176,"class":177},"Casa di Cura San Raffaele Cassino","NETWORK"]